SEC Comment Letter for SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Sep 20, 2016
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Sept. 20, 2016 · CIK: 0001390478 · Accession: 0000000000-16-093626
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4 546 September 20, 2016 Dr. Mark W. Schwartz President & Chief Executive Officer Galena Biopharma, Inc. 2000 Crow Canyon Place, Suite 380 San Ramon, California 94583
Re: Galena Biopharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 9, 2016 Revised Preliminary Proxy Statement on Schedule 14A Filed September 19, 2016 File No. 001 -33958
Dear Dr. Schwartz :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceedi ng initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the informati on the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4 546 September 20, 2016 Dr. Mark W. Schwartz President & Chief Executive Officer Galena Biopharma, Inc. 2000 Crow Canyon Place, Suite 380 San Ramon, California 94583 Re: Galena Biopharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 9, 2016 Revised Preliminary Proxy Statement on Schedule 14A Filed September 19, 2016 File No. 001 -33958 Dear Dr. Schwartz : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceedi ng initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the informati on the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance